Breast Cancer Coverage from Every Angle

Marleen Kok, MD, PhD, on Preoperative Nivolumab for Triple-Negative Breast Cancer: Initial Results From the BELLINI Trial

Posted: Monday, October 3, 2022

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the clinical implications of her findings on the use of short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, to induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.